Current Science

The PDF file you selected should load here if your Web browser has a PDF reader plug-in installed (for example, a recent version of Adobe Acrobat Reader).

If you would like more information about how to print, save, and work with PDFs, Highwire Press provides a helpful Frequently Asked Questions about PDFs.

Alternatively, you can download the PDF file directly to your computer, from where it can be opened using a PDF reader. To download the PDF, click the Download link above.

Fullscreen Fullscreen Off


Insulin-like growth factor II promoter 3 (IGF-IIP3) is the most active promoter in live cancer cells. In this study, the anti-tumour growth effects of DRz1 were measured in a model of hepatoma-bearing mice. DRz1 significantly inhibited IGF-IIP3 expression and tumour growth in vivo. Compared to the sham-treated control group, DRz1 treatment attenuated the tumour volume and weight after 14 days of treatment. DRz1 could significantly inhibit the expression of IGF-IIP3, could inhibit the associated tumour-promoting proteins and could retard the growth of hepatocarcinoma tumours in vivo. These findings provide novel evidence for the anti-tumour effects of DRz1 in vivo.

Keywords

Anti-Tumour Growth, Bearing Mouse Model, Hepatocellular Carcinoma, IGF-IIP3-DRz1.
User
Notifications
Font Size